Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

91.28 +1.30 (+1.44%)
Streaming Delayed Price Updated: 1:21 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 226,098
Open 90.00
Bid (Size) 90.90 (100)
Ask (Size) 91.66 (100)
Prev. Close 89.98
Today's Range 89.97 - 93.24
52wk Range 47.86 - 96.39
Shares Outstanding 48,358,981
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcellx Provides Third Quarter 2025 Financial Results
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire

Performance

YTD
+15.9%
+15.9%
1 Month
+4.9%
+4.9%
3 Month
+27.1%
+27.1%
6 Month
+56.0%
+56.0%
1 Year
+3.5%
+3.5%

More News

Read More
News headline image
Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference
From Arcellx, Inc.
Via Business Wire
News headline image
4 Analysts Assess Arcellx: What You Need To Know ↗
Via Benzinga
News headline image
(ACLX) - Analyzing Arcellx's Short Interest ↗
Via Benzinga
News headline image
In-Depth Examination Of 14 Analyst Recommendations For Arcellx ↗
Via Benzinga
News headline image
Arcellx (ACLX) Q2 Revenue Drops 72% ↗
Via The Motley Fool
News headline image
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
News headline image
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Via Investor's Business Daily
Topics Government
News headline image
14 Analysts Have This To Say About Arcellx ↗
Via Benzinga
News headline image
Analyst Expectations For Arcellx's Future ↗
Via Benzinga
News headline image
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
From Arcellx, Inc.
Via Business Wire
News headline image
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
News headline image
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
From Arcellx, Inc.
Via Business Wire
News headline image
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗
Via Benzinga
News headline image
Arcellx Stock Earns 82 Relative Strength Rating ↗
Via Investor's Business Daily
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
Via Investor's Business Daily
News headline image
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗
Via Benzinga
News headline image
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire

Frequently Asked Questions

Is Arcellx, Inc. - Common Stock publicly traded?
Yes, Arcellx, Inc. - Common Stock is publicly traded.
What exchange does Arcellx, Inc. - Common Stock trade on?
Arcellx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcellx, Inc. - Common Stock?
The ticker symbol for Arcellx, Inc. - Common Stock is ACLX on the Nasdaq Stock Market
What is the current price of Arcellx, Inc. - Common Stock?
The current price of Arcellx, Inc. - Common Stock is 91.28
When was Arcellx, Inc. - Common Stock last traded?
The last trade of Arcellx, Inc. - Common Stock was at 11/17/25 01:21 PM ET
What is the market capitalization of Arcellx, Inc. - Common Stock?
The market capitalization of Arcellx, Inc. - Common Stock is 4.41B
How many shares of Arcellx, Inc. - Common Stock are outstanding?
Arcellx, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.